Sunny Pharmtech

Sunny Pharmtech FCF per Share

The Free Cash Flow per Share of Sunny Pharmtech (6676.TWO) as of Nov 22, 2026 is -0.58 TWD. In the previous year, Free Cash Flow per Share was -0.73 TWD — a change of -20.14% (higher).

FCF per Share

-0.58TWD

YoY

-20.14%

Last updated:

Free Cash Flow per Share of Sunny Pharmtech is 2024 -0.58 TWD. Free Cash Flow per Share of Sunny Pharmtech was 2023 -0.73 TWD. It decreases by -20.14% higher compared to the previous year.

The Sunny Pharmtech FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-4.03 TWD
Jan 1, 2019
-1.53 TWD
Jan 1, 2020
-0.72 TWD
Jan 1, 2021
-1.43 TWD
Jan 1, 2022
-1.22 TWD
Jan 1, 2023
-0.73 TWD
Jan 1, 2024
-0.58 TWD
The Sunny Pharmtech FCF per Share history
YEARFCF per ShareYoY
-0.58TWD-20.14%
-0.73TWD-40.05%
-1.22TWD-14.85%
-1.43TWD+97.88%
-0.72TWD-52.81%
-1.53TWD-62.06%
-4.03TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sunny Pharmtech Stock analysis

What does Sunny Pharmtech do? Sunny Pharmtech Inc develops, manufactures, and markets generic and 505(b)2 drug products, primarily targeting the United States market. The company's main products include lectin drug complex (LDC) anesthesia analgesic ointment, neurofibrillary tangle (NFT) anti-urinary tract infection capsules, anti-mitochondrial antibody (AMA) hemostatic lozenges, cyclosporine A (CYA) injections for anemia, and campto (CPT) gynecological injections. These products are sold directly to customers in the United States, generating revenue through pharmaceutical sales. The company focuses on developing and commercializing specialized drug formulations, with its product portfolio centered on LDC, NFT, AMA, CYA, and CPT branded medications. Sales are concentrated in the United States, where the firm's generic and 505(b)2 drug products are marketed to healthcare providers and pharmacies. Revenue is derived from the direct sale of these pharmaceutical products to U.S. customers. Sunny Pharmtech Inc's business model relies on the development and marketing of its proprietary drug formulations, including LDC, NFT, AMA, CYA, and CPT products, which are sold to the United States market. The company's revenue stream is generated through the sale of these branded pharmaceutical products to U.S. healthcare institutions and retail pharmacies. Sunny Pharmtech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunny Pharmtech stock

Free Cash Flow per Share of Sunny Pharmtech is -0.58 TWD in 2024.

Free Cash Flow per Share of Sunny Pharmtech changed from -0.73 TWD to -0.58 TWD, representing a -20.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Sunny Pharmtech since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Sunny Pharmtech

All Key Metrics — Sunny Pharmtech